Literature DB >> 17670967

Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path.

Raad Nashmi1, Cheng Xiao, Purnima Deshpande, Sheri McKinney, Sharon R Grady, Paul Whiteaker, Qi Huang, Tristan McClure-Begley, Jon M Lindstrom, Cesar Labarca, Allan C Collins, Michael J Marks, Henry A Lester.   

Abstract

Understanding effects of chronic nicotine requires identifying the neurons and synapses whose responses to nicotine itself, and to endogenous acetylcholine, are altered by continued exposure to the drug. To address this problem, we developed mice whose alpha4 nicotinic receptor subunits are replaced by normally functioning fluorescently tagged subunits, providing quantitative studies of receptor regulation at micrometer resolution. Chronic nicotine increased alpha4 fluorescence in several regions; among these, midbrain and hippocampus were assessed functionally. Although the midbrain dopaminergic system dominates reward pathways, chronic nicotine does not change alpha4* receptor levels in dopaminergic neurons of ventral tegmental area (VTA) or substantia nigra pars compacta. Instead, upregulated, functional alpha4* receptors localize to the GABAergic neurons of the VTA and substantia nigra pars reticulata. In consequence, GABAergic neurons from chronically nicotine-treated mice have a higher basal firing rate and respond more strongly to nicotine; because of the resulting increased inhibition, dopaminergic neurons have lower basal firing and decreased response to nicotine. In hippocampus, chronic exposure to nicotine also increases alpha4* fluorescence on glutamatergic axons of the medial perforant path. In hippocampal slices from chronically treated animals, acute exposure to nicotine during tetanic stimuli enhances induction of long-term potentiation in the medial perforant path, showing that the upregulated alpha4* receptors in this pathway are also functional. The pattern of cell-specific upregulation of functional alpha4* receptors therefore provides a possible explanation for two effects of chronic nicotine: sensitization of synaptic transmission in forebrain and tolerance of dopaminergic neuron firing in midbrain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17670967      PMCID: PMC6673074          DOI: 10.1523/JNEUROSCI.2199-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  104 in total

Review 1.  Role of dopamine in the behavioural actions of nicotine related to addiction.

Authors:  G Di Chiara
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

2.  Acute and chronic nicotine exposure differentially facilitate the induction of LTP.

Authors:  S Fujii; Z Ji; N Morita; K Sumikawa
Journal:  Brain Res       Date:  1999-10-30       Impact factor: 3.252

Review 3.  Presynaptic ionotropic receptors and the control of transmitter release.

Authors:  A B MacDermott; L W Role; S A Siegelbaum
Journal:  Annu Rev Neurosci       Date:  1999       Impact factor: 12.449

4.  Differential changes in accumbens shell and core dopamine in behavioral sensitization to nicotine.

Authors:  C Cadoni; G Di Chiara
Journal:  Eur J Pharmacol       Date:  2000-01-17       Impact factor: 4.432

5.  Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit.

Authors:  M J Marks; P Whiteaker; J Calcaterra; J A Stitzel; A E Bullock; S R Grady; M R Picciotto; J P Changeux; A C Collins
Journal:  J Pharmacol Exp Ther       Date:  1999-05       Impact factor: 4.030

6.  Reduced antinociception in mice lacking neuronal nicotinic receptor subunits.

Authors:  L M Marubio; M del Mar Arroyo-Jimenez; M Cordero-Erausquin; C Léna; N Le Novère; A de Kerchove d'Exaerde; M Huchet; M I Damaj; J P Changeux
Journal:  Nature       Date:  1999-04-29       Impact factor: 49.962

7.  Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum.

Authors:  S R Grady; N M Meinerz; J Cao; A M Reynolds; M R Picciotto; J P Changeux; J M McIntosh; M J Marks; A C Collins
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

8.  Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse.

Authors:  S A Ross; J Y Wong; J J Clifford; A Kinsella; J S Massalas; M K Horne; I E Scheffer; I Kola; J L Waddington; S F Berkovic; J Drago
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

9.  A comparison of the effects of nicotine on dopamine and non-dopamine neurons in the rat ventral tegmental area: an in vitro electrophysiological study.

Authors:  R Yin; E D French
Journal:  Brain Res Bull       Date:  2000-04       Impact factor: 4.077

10.  Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei.

Authors:  R Klink; A de Kerchove d'Exaerde ; M Zoli; J P Changeux
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

View more
  140 in total

1.  Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior.

Authors:  B N Cohen; E D W Mackey; S R Grady; S McKinney; N E Patzlaff; C R Wageman; J M McIntosh; M J Marks; H A Lester; R M Drenan
Journal:  Neuroscience       Date:  2011-11-04       Impact factor: 3.590

Review 2.  Regulation of hippocampal inhibitory circuits by nicotinic acetylcholine receptors.

Authors:  Marilena Griguoli; Enrico Cherubini
Journal:  J Physiol       Date:  2011-11-28       Impact factor: 5.182

3.  Regulation of the distribution and function of [(125)I]epibatidine binding sites by chronic nicotine in mouse embryonic neuronal cultures.

Authors:  Cristian A Zambrano; Rakel M Salamander; Allan C Collins; Sharon R Grady; Michael J Marks
Journal:  J Pharmacol Exp Ther       Date:  2012-04-24       Impact factor: 4.030

4.  Sex differences in availability of β2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers.

Authors:  Kelly P Cosgrove; Irina Esterlis; Sherry A McKee; Frederic Bois; John P Seibyl; Carolyn M Mazure; Suchitra Krishnan-Sarin; Julie K Staley; Marina R Picciotto; Stephanie S O'Malley
Journal:  Arch Gen Psychiatry       Date:  2012-04

5.  Spectral confocal imaging of fluorescently tagged nicotinic receptors in knock-in mice with chronic nicotine administration.

Authors:  Anthony Renda; Raad Nashmi
Journal:  J Vis Exp       Date:  2012-02-10       Impact factor: 1.355

6.  Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.

Authors:  Sharon R Grady; Ryan M Drenan; Scott R Breining; Daniel Yohannes; Charles R Wageman; Nikolai B Fedorov; Sheri McKinney; Paul Whiteaker; Merouane Bencherif; Henry A Lester; Michael J Marks
Journal:  Neuropharmacology       Date:  2010-01-28       Impact factor: 5.250

7.  Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Andrew M Smith; Marharyta Pivavarchyk; Thomas E Wooters; Zhenfa Zhang; Guangrong Zheng; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

Review 8.  Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction.

Authors:  Ruthie E Wittenberg; Shannon L Wolfman; Mariella De Biasi; John A Dani
Journal:  Neuropharmacology       Date:  2020-07-29       Impact factor: 5.250

Review 9.  Molecular mechanisms of acetylcholine receptor-lipid interactions: from model membranes to human biology.

Authors:  John E Baenziger; Corrie J B daCosta
Journal:  Biophys Rev       Date:  2012-05-10

10.  Nicotine normalizes intracellular subunit stoichiometry of nicotinic receptors carrying mutations linked to autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Cagdas D Son; Fraser J Moss; Bruce N Cohen; Henry A Lester
Journal:  Mol Pharmacol       Date:  2009-02-23       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.